RELMADA THERAPEUTICS, INC.

RLMDSEC EDGAR

Pharmaceutical Preparations(NV)CIK: 1553643

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	—	—	—	—	—
Cost of Goods and Services Sold	—	—	—	—	—
Gross Profit	—	—	—	—	—
Research and Development Expense	$54.8M	$113.3M	$90.6M	$36.0M	$7.0M
Operating Expenses	$103.7M	$161.2M	$125.7M	$60.8M	$12.7M
Operating Income (Loss)	-$103.7M	-$161.2M	-$125.7M	-$60.8M	-$12.7M
Interest Expense	—	—	—	—	—
Nonoperating Income (Expense)	$4.9M	$4.2M	-$48.3K	$1.4M	-$4.6M
Net Income (Loss) Attributable to Parent	-$98.8M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$97.6M	$152.9M	$223.3M	$118.2M	$10.2M
Assets, Current	$97.5M	$152.9M	$223.3M	$118.1M	$10.0M
Cash and Cash Equivalents, at Carrying Value	$4.1M	$5.4M	$44.4M	—	$2.2M
Liabilities	$12.2M	$12.5M	$15.1M	$12.6M	$2.6M
Liabilities, Current	$12.2M	$12.5M	$15.1M	$12.6M	$2.6M
Accounts Payable, Current	$3.5M	$5.3M	$11.2M	$8.3M	$924.4K
Stockholders' Equity Attributable to Parent	$140.4M	$208.3M	$105.6M	$115.7M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$51.7M	-$103.8M	-$91.9M	-$27.8M	-$10.5M
Net Cash Provided by (Used in) Investing Activities	$50.5M	$19.7M	-$54.1M	-$34.4M	-$80.2M
Net Cash Provided by (Used in) Financing Activities	-$98.5K	$45.0M	$187.9M	$28.5M	$17.5M
Payments to Acquire Property, Plant, and Equipment	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)